JPWO2021235392A1 - - Google Patents

Info

Publication number
JPWO2021235392A1
JPWO2021235392A1 JP2022524462A JP2022524462A JPWO2021235392A1 JP WO2021235392 A1 JPWO2021235392 A1 JP WO2021235392A1 JP 2022524462 A JP2022524462 A JP 2022524462A JP 2022524462 A JP2022524462 A JP 2022524462A JP WO2021235392 A1 JPWO2021235392 A1 JP WO2021235392A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022524462A
Other languages
Japanese (ja)
Other versions
JP7765835B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021235392A1 publication Critical patent/JPWO2021235392A1/ja
Application granted granted Critical
Publication of JP7765835B2 publication Critical patent/JP7765835B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022524462A 2020-05-18 2021-05-17 抗ＳＡＲＳ－ＣｏＶ－２薬 Active JP7765835B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020086517 2020-05-18
JP2020086517 2020-05-18
PCT/JP2021/018617 WO2021235392A1 (ja) 2020-05-18 2021-05-17 抗ＳＡＲＳ－ＣｏＶ－２薬

Publications (2)

Publication Number Publication Date
JPWO2021235392A1 true JPWO2021235392A1 (https=) 2021-11-25
JP7765835B2 JP7765835B2 (ja) 2025-11-07

Family

ID=78708496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022524462A Active JP7765835B2 (ja) 2020-05-18 2021-05-17 抗ＳＡＲＳ－ＣｏＶ－２薬

Country Status (4)

Country Link
US (1) US20230192622A1 (https=)
EP (1) EP4154884A4 (https=)
JP (1) JP7765835B2 (https=)
WO (1) WO2021235392A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023085432A1 (https=) * 2021-11-15 2023-05-19
WO2024237331A1 (ja) * 2023-05-17 2024-11-21 オンコリスバイオファーマ株式会社 フェナントリジノン誘導体のコリン塩

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011093483A1 (ja) * 2010-02-01 2011-08-04 国立大学法人鹿児島大学 C型肝炎治療剤
CN110960532A (zh) * 2020-02-21 2020-04-07 金晓飞 一种抗冠状病毒的博落回苄基异喹啉类生物碱与白藜芦醇组合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020086517A (ja) 2018-11-15 2020-06-04 キヤノン株式会社 情報処理装置及びその制御方法とプログラム

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011093483A1 (ja) * 2010-02-01 2011-08-04 国立大学法人鹿児島大学 C型肝炎治療剤
CN110960532A (zh) * 2020-02-21 2020-04-07 金晓飞 一种抗冠状病毒的博落回苄基异喹啉类生物碱与白藜芦醇组合物及其应用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AOYAMA, HIROSHI ET AL.: "Fused heterocyclic amido compounds as anti-hepatitis C virus agents", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 19, no. 8, JPN6021025834, 2011, pages 2675 - 2687, XP055439664, ISSN: 0005613939, DOI: 10.1016/j.bmc.2011.03.002 *
LIN, SHING-YEN ET AL.: "Structural Basis for the Identification of the N-Terminal Domain of Coronavirus Nucleocapsid Protein", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 6, JPN6021025837, 2014, pages 2247 - 2257, XP055875268, ISSN: 0005613942, DOI: 10.1021/jm500089r *
NISHIYAMA, YUKO ET AL.: "Novel Nonsteroidal Progesterone Receptor (PR) Antagonists with a Phenanthridinone Skeleton", ACS MEDICINAL CHEMISTRY LETTERS, vol. 9, no. 7, JPN6021025836, 2018, pages 641 - 645, XP055875267, ISSN: 0005613941, DOI: 10.1021/acsmedchemlett.8b00058 *
NISHIYAMA, YUKO ET AL.: "Structure-activity relationship-guided development of retinoic acid receptor-related orphan receptor", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 22, no. 9, JPN6021025835, 2014, pages 2799 - 2808, XP055875264, ISSN: 0005613940, DOI: 10.1016/j.bmc.2014.03.007 *
RASOOL, NOUMAN ET AL.: "Insights into the inhibitory potential of selective phytochemicals against Mpro of 2019-nCoV: a comp", STRUCTURAL CHEMISTRY, vol. 31, no. 5, JPN6021025832, 1 May 2020 (2020-05-01), pages 1777 - 1783, XP038181568, ISSN: 0005613938, DOI: 10.1007/s11224-020-01536-6 *
ZUMLA, ALIMUDDIN ET AL.: "Coronaviruses-drug discovery and therapeutic options", NATURE REVIEWS DRUG DISCOVERY, vol. 15, no. 5, JPN6021025838, 2016, pages 327 - 347, XP037065530, ISSN: 0005613943, DOI: 10.1038/nrd.2015.37 *

Also Published As

Publication number Publication date
JP7765835B2 (ja) 2025-11-07
EP4154884A1 (en) 2023-03-29
EP4154884A4 (en) 2024-05-29
US20230192622A1 (en) 2023-06-22
WO2021235392A1 (ja) 2021-11-25

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250808

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250924

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251020

R150 Certificate of patent or registration of utility model

Ref document number: 7765835

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150